Surgical Outcomes After Neoadjuvant Chemotherapy and Ipilimumab for Non-Small Cell Lung Cancer

Yang, Chi‐Fu Jeffrey; McSherry, Frances; Mayne, Nicholas R.; Wang, Xiaofei; Berry, Mark F.; Tong, Betty C.; Harpole, David H.; D’Amico, Thomas A.; Christensen, Jared D.; Ready, Neal; Klapper, Jacob A.

doi:10.1016/j.athoracsur.2017.09.030

Cited by 102 publications

(111 citation statements)

References 15 publications

(13 reference statements)

Supporting

Mentioning

101

Contrasting

Order By: Relevance

“…Most of the available studies were performed in advanced/metastatic recurrent NSCLC. Two studies were done in the neoadjuvant setting (25)(26)(27)(28). In a phase I study (25,26), 21 eligible patients with stage IB-IIIA resectable NSCLC received two doses of nivolumab (3 mg/kg) on days 28 and 14 before surgical resection.…”

Section: Phase I-ii Studiesmentioning

confidence: 99%

“…No unexpected adverse event and no operative mortality were observed (26). The primary objective of the phase II study (27,28) was "to assess whether the appearance of T cells activated against select tumor-associated antigens (TAA) increased from baseline following treatment with ipilimumab" and this endpoint was not met. Twenty-four stage IIA-IIIA NSCLC received 3 cycles of induction cisplatin or carboplatin plus paclitaxel with ipilimumab (10 mg/kg) during cycles 2 and 3.…”

Section: Phase I-ii Studiesmentioning

confidence: 99%

“…Pharmacoeconomic analyses from randomized trials.LYG, life year gained; QALY, quality adjusted life years.stage I-III NSCLC showed major pathological responses, despite sometimes a poor clinical response rate after a short period of treatment(25)(26)(27)(28). Other trials are on the way for induction before surgery [Atezolizumab in Stage IB, II, or IIIA (NCT02927301), Durvalumab (NCT03030131), Nivolumab in Stage IB-IIIA (NCT02595944), Pembrolizumab in N2 disease (NCT03053856)]…”

mentioning

confidence: 99%

See 2 more Smart Citations

Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept

et al. 2020

View full text Add to dashboard Cite

Immunotherapy in lung cancer treatment is a long history paved with failures and some successes. During the last decade, the discovery of checkpoints inhibitors led to major advances in treating advanced and metastatic non-small cell lung cancer (NSCLC). Impressive data from early phase I-II studies were subsequently confirmed in large prospective randomized trials and meta-analyses (High-level of evidence). Three anti-programmed death-1 (PD1) (pembrolizumab, nivolumab) or antiPD-ligand(L)1 (atezolizumab) antibodies showed clinically significant improved survival compared to second-line docetaxel. Then, first-line pembrolizumab monotherapy demonstrated its superiority over platinum-doublet in high PD-L1 NSCLC. The addition of pembrolizumab or atezolizumab to chemotherapy derived the same results regardless of the PD-L1 status. On the opposite, antiCTLA4 (Cytotoxic T-Lymphocyte Associated 4) results are currently disappointing in unselected patients while recent development suggest that the combination of antiPD1 and antiCTLA4 (nivolumab-ipilimumab) positively impact on overall survival. Some secondary analyses also showed that immunotherapy has a positive impact on quality of life and that the clinical improvement can be done at an acceptable incremental cost per QALY. A lot of questions remain unresolved: which is the best treatment duration and is it the same for all patients, how to choose the patients that will have the highest benefit of immunotherapy, how to identify the patients who will have rapid progression, how to improve the current data (new targets, new combinations)…

show abstract

Section: Phase I-ii Studiesmentioning

confidence: 99%

Section: Phase I-ii Studiesmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept

et al. 2020

View full text Add to dashboard Cite

show abstract

“…26 These low mortality rates may continue with neoadjuvant immunotherapy. Yang and colleagues 27 reported a 0% mortality for 13 patients (10/13 IIIA) given neoadjuvant ipilimumab with a platinum doublet in the TOP1201 trial and no difference in morbidity rates from those previously reported in other preoperative chemotherapy trials. Despite these encouraging results, future studies will need to define morbidity and mortality as it relates to the addition of immunotherapies and toxicities that were well described previously.…”

Section: Safety Of Stage Iiia Surgerymentioning

confidence: 87%

PACIFIC: Time for a surgical IIIA uprising

Pass

2018

The Journal of Thoracic and Cardiovascular Surgery

View full text Add to dashboard Cite

Feature Editor's Note-If you are not already committed based on the title alone, this is an article that should be read by all thoracic surgical oncologists. The PACIFIC trial is randomized trial recently published in the New England Journal of Medicine that showed improvement in progression-free survival in patients with unresectable stage IIIA-B non-small cell lung cancer treated with PD-L1 blockade (compared with placebo) after

show abstract

“…Regardless, the association between cell proliferation and immune suppression in stage I cancers holds relevance, as stage IB tumors are often included in trials of neoadjuvant and adjuvant T-cell checkpoint inhibition in NSCLC. 7,8 Therefore, if Ki67 expression does predict response to therapy, this might help to select patients for this treatment approach. The authors' finding that high Ki67 expression (>25% of tumor cells) was associated with increased mortality may provide an additional rationale for the use of multimodality treatment in this patient population.…”

Section: Matthew J Bott MDmentioning

confidence: 99%